Concomitant use of tamoxifen and endoxifen in postmenopausal early breast cancer: prediction of plasma levels by physiologically-based pharmacokinetic modeling
Abstract:
To overcome cytochrome P450 2D6 (CYP2D6) mediated tamoxifen resistance in postmenopausal early breast cancer, CYP2D6 phenotype-adjusted tamoxifen dosing in patients with impaired CYP2D6 metabolism and/or the application of endoxifen, the most potent tamoxifen metabolite, are alternative treatment options. To elucidate both strategies comprehensively we used a physiologically-based pharmacokinetic (PBPK) modeling approach.
Projects: G3: Clinical Translation to Pharmaceutical Drug Development
Springerplus
Springerplus 3: 285
5th Jun 2014
Kristin Dickschen, Thomas Eissing, Thomas Mürdter, Matthias Schwab, Stefan Willmann, Georg Hempel
Authors
Attributions
None
Scales
Not Specified
- Created: 7th Apr 2015 at 14:48
Related items
